US Patent

US11673877 — Niraparib compositions

Method of Use · Assigned to Merck Sharp and Dohme LLC · Expires 2038-03-27 · 12y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compositions of the compound niraparib, specifically certain solid forms of niraparib.

USPTO Abstract

The present invention relates to compositions comprising the compound niraparib, in particular certain solid forms of niraparib.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2830`	—
`U-3646`	—
`U-3647`	—
`U-3646`	—
`U-2830`	—
`U-3647`	—

Patent Metadata

Patent number: US11673877
Jurisdiction: US
Classification: Method of Use
Expires: 2038-03-27
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Merck Sharp and Dohme LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.